Back to search results

Meal Timing During Cancer Adjuvant Treatment

This study is exploring if changing when you eat, called time-restricted eating, can help people undergoing cancer treatment. Specifically, it's for adults (18 years and older) who have had surgery for a solid tumor and are starting additional treatments like chemotherapy, targeted therapy, or immunotherapy. The study wants to see if time-restricted eating can reduce treatment side effects, help you complete your planned treatment, and improve your overall well-being. Participants will either follow an 8-hour daily eating period or a more typical eating schedule of 12 hours or more. Researchers will track your eating times, ask you to complete questionnaires, and collect blood and stool samples. The study is currently unclear on its recruitment status and plans to enroll 50 participants.

Study design
This is an interventional study where participants will be randomly assigned to one of two groups: time-restricted eating or a control group. The study plans to enroll 50 participants.
What's involved
You would be asked to record your eating times daily, complete questionnaires, and provide blood and stool samples. You would also receive health coaching. This commitment lasts for approximately 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your treatment-related side effects and treatment delivery will be measured weekly and at the end of the intervention, which is approximately 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07524218

Effect of Meal Timing During Adjuvant Treatment for Cancer

Recruiting
NAAges 18+InterventionalTreatment
Fred Hutchinson Cancer Center
~50 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Time-restricted eatingQuestionnaire AdministrationBiospecimen CollectionHealth coaching

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient-reported treatment-related toxicities: Average weekly scores
Measured over Assessed weekly from start of intervention through end of intervention (up to approximately 6 months)
+2 more outcomes measured

Conditions

Cancer

Explore related trials

Solid Neoplasm

NCT07524218

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars Sinai Medical Center (CSMC)

    Los Angeles, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jane Figueiredo, PhD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
  • Timothy Thomas, MD · PRINCIPAL_INVESTIGATOR · Alaska Native Tribal Health Consortium (ANTHC)

Who to contact

Jane Figueiredo, PhD
[email protected]
(310) 423-2746
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years (no upper age limit)
Any sex or gender
Histologically or cytologically confirmed solid tumor treated with curative-intent surgical resection and planned initiation of systemic adjuvant therapy (chemotherapy, targeted therapy, immunotherapy, and/or radiation per standard of care)
BMI ≥18.5 kg/m2
Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions

Exclusion

No plan for systemic adjuvant therapy after surgery
Strictly adhering to a \<10-hour eating window on most days
Regular overnight shift work (≥1 night shift per week)
Dependent on parenteral or enteral nutrition
Pregnant or breastfeeding
Active second malignancy requiring systemic therapy (exceptions: non-melanoma skin cancers or in situ cervical cancers adequately treated)
Severe psychiatric, cognitive, or social conditions that would interfere with adherence to study procedures

What this trial measures

  • Patient-reported treatment-related toxicities: Average weekly scoresAssessed weekly from start of intervention through end of intervention (up to approximately 6 months)

    Assessed via Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE v5) toxicities, which is administered weekly throughout intervention and therapy; average scores calculated at each time point, timed to oncologic treatment cycles.

  • Treatment Delivery: Relative dose intensity (RDI)At end of intervention (at approximately 6 months)

    Relative dose intensity (RDI), defined as delivered/planned dose intensity, will be analyzed both as a continuous outcome (% of delivered vs planned) and as a binary outcome (≥85% vs. \< 85%). Regimen-level RDI will be calculated as the average across drugs or based on the dose-limiting agent.

  • Treatment Delivery: Number of patients completing planned adjuvant therapy without unplanned dose reductions or delaysAt end of intervention (at approximately 6 monhts)